Bintrafusp alfa, a first-in-class bifunctional fusion protein targeting TGF-β and PD-L1, showed encouraging efficacy as a second-line therapy for NSCLC patients in dose-expansion cohorts of an open-label Phase I trial. This evidence concerns the gene CD274 and non-small cell lung carcinoma.